Serina Therapeutics (SER)
:SER
Top Page
Serina Therapeutics
(SER)
Select Model
Select Model
Rating:43Neutral
Price Target:
$2.00
▼(-3.85% Downside)
Action:ReiteratedDate:03/31/26
The score is primarily held down by weak financial performance (minimal/volatile revenue, large losses, and sustained cash burn) and a bearish long-term technical trend (price below key moving averages). Corporate events modestly offset this via improved financing runway, but listing-compliance risk and a negative/less-informative P/E keep overall risk elevated.
Positive Factors
Platform & Focus
Serina’s polymer conjugate platform targets long-acting, controlled-release formulations for CNS and chronic diseases. That platform-level approach creates durable technical differentiation and multiple application pathways, increasing partnership and licensing optionality beyond any single asset.
Negative Factors
Sustained Cash Burn
Persistent negative operating and free cash flow at ~-$18M annually exhausts resources absent recurring revenue, forcing repeated external financings. This structural burn increases dilution risk, compresses management focus on financing over development, and raises the probability of capital-access constraints within months.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform & Focus
Serina’s polymer conjugate platform targets long-acting, controlled-release formulations for CNS and chronic diseases. That platform-level approach creates durable technical differentiation and multiple application pathways, increasing partnership and licensing optionality beyond any single asset.
Read all positive factors
Serina Therapeutics (SER) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$25.61M
Dividend YieldN/A
Average Volume (3M)24.47K
Price to Earnings (P/E)―
Beta (1Y)-0.10
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees12
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.31
Shares Outstanding12,314,159
10 Day Avg. Volume14,098
30 Day Avg. Volume24,472
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-526.02
Price to Sales (P/S)149.71
P/FCF Ratio-1.08
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue156.05
Enterprise Value/Gross Profit355.89
Enterprise Value/Ebitda-0.92
Forecast
1Y Price Target
$11.00Price Target Upside428.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.82
Revenue Forecast (FY)N/A
Serina Therapeutics Business Overview & Revenue Model
Company Description
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long...
How the Company Makes Money
null...
Serina Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
15
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 130.00K | 56.00K | 3.15M | 500.00K | 3.46M |
| Gross Profit | 45.00K | -138.00K | 3.06M | 500.00K | -333.84K |
| EBITDA | -24.02M | -10.49M | 5.92M | -2.60M | -1.23M |
| Net Income | -19.18M | -11.14M | 5.27M | -2.68M | -1.26M |
Balance Sheet | |||||
| Total Assets | 6.95M | 6.72M | 8.97M | 3.24M | 3.15M |
| Cash, Cash Equivalents and Short-Term Investments | 3.06M | 3.67M | 7.62M | 645.00K | 584.00K |
| Total Debt | 196.00K | 268.00K | 3.44M | 18.12M | 13.20M |
| Total Liabilities | 6.99M | 6.22M | 41.26M | 20.56M | 15.03M |
| Stockholders Equity | -37.00K | 641.00K | 4.11M | -17.21M | -11.83M |
Cash Flow | |||||
| Free Cash Flow | -17.95M | -17.16M | -2.98M | -2.09M | -2.36M |
| Operating Cash Flow | -17.95M | -17.14M | -2.48M | -2.08M | -2.25M |
| Investing Cash Flow | -59.00K | -22.00K | -504.00K | 980.94K | 823.32K |
| Financing Cash Flow | 17.41M | 13.21M | 10.07M | 1.31M | 1.08M |
Serina Therapeutics Technical Analysis
Negative
2.08
Price Trends
2.07
Negative
2.57
Negative
3.90
Negative
Market Momentum
0.04
Positive
48.89
Neutral
25.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SER, the sentiment is Negative. The current price of 2.08 is above the 20-day moving average (MA) of 2.07, above the 50-day MA of 2.07, and below the 200-day MA of 3.90, indicating a bearish trend. The MACD of 0.04 indicates Positive momentum. The RSI at 48.89 is Neutral, neither overbought nor oversold. The STOCH value of 25.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SER.
Serina Therapeutics Risk Analysis
Serina Therapeutics disclosed 78 risk factors in its most recent earnings report. Serina Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Serina Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $23.57M | -0.53 | -143.59% | ― | ― | -53.18% | |
44 Neutral | $40.08M | -0.59 | 763.31% | ― | -15.81% | -113.06% | |
44 Neutral | $22.10M | -0.43 | -70.57% | ― | -100.00% | -26.30% | |
43 Neutral | $25.61M | -1.46 | -1259.21% | ― | ― | ― | |
40 Underperform | $22.28M | -1.03 | 293.07% | ― | ― | 86.28% |
* Healthcare Sector Average
SER
Serina Therapeutics
2.02
-3.02
-59.92%
OTLK
Outlook Therapeutics
0.25
-0.95
-79.17%
SKYE
Skye Bioscience
0.71
-0.64
-47.63%
CELU
Celularity
1.37
-0.20
-12.74%
BRNS
Barinthus Biotherapeutics
0.59
-0.10
-14.14%
JUNS
Jupiter Neurosciences, Inc.
0.37
-0.19
-33.57%
Serina Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and Financing
Serina Therapeutics Announces Premium Private Placement Financing
Positive
Mar 23, 2026
On March 17, 2026, Serina Therapeutics entered into a securities purchase agreement for a private placement of common stock, pre-funded warrants and redeemable warrants led by board director Greg Bailey, with an initial $15 million tranche that in...
Delistings and Listing ChangesFinancial DisclosuresRegulatory Filings and Compliance
Serina Therapeutics Faces NYSE American Compliance Deficiency Notice
Negative
Jan 15, 2026
On January 9, 2026, Serina Therapeutics received a deficiency notification from NYSE American stating the company is not in compliance with the exchange’s minimum stockholders’ equity requirements, after reporting equity of $1.6 millio...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.